Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Wednesday’s Pre-Market Insights: PBR, SDRL, NSPH, WDAY

Published 05/27/2015, 08:04 AM
Updated 05/14/2017, 06:45 AM

Petroleo Brasileiro Petrobras SA (NYSE:PBR) shares increased 4.11% to $8.86 in Wednesday’s pre-market trading following news that the Brazilian government is considering making concessions to local contractors in an attempt to revitalize Brazil’s flailing economy. The energy corporation is one of the largest corporations in Latin America when measured by revenue.

Seadrill Limited (NYSE:SDRL) shares fell 0.70% in pre-market trading to $12.82 as the offshore drilling company has been trying to survive through tumultuous oil prices. Seadrill will be releasing quarterly earnings tomorrow and investors will be looking at the company’s liquidity after Seadrill suspended dividends as well as their plans to build new rigs.

Nanosphere Inc (NASDAQ:NSPH) shares increased nearly 13% to $4.00 after SWK Holdings Corp increased their stake in the diagnostic test company to 6.4%. SWK is a finance company that specializes in the healthcare sector.


Workday Inc (NYSE:WDAY) shares are down 7.45% to $85.60 after the company released earnings in which they posted a loss of $(0.02), missing the analyst estimate of $0.08. The management software company forecast billings for the second quarter to be between $290 million and $295 million, falling short of analysts’ estimates of $303 million.


Additionally, the following stocks were rated yesterday:


EMC Corporation (NYSE:EMC) received two BULLISH ratings from Aaron Rakers of Stifel Nicolaus and Daniel Ives of FBR Capital after the company announced it will be acquiring Virtustream in an all-cash deal of $1.2 billion. Analysts see this move as EMC’s attempt to break further into the cloud market.

Bluebird bio Inc (NASDAQ:BLUE) received two BULLISH ratings from Debjit Chattopadhyay of Roth Capital and Joshua Schimmer of Piper Jaffray after the biopharmaceutical company announced an exclusive license agreement with Five Prime Therapeutics to collaborate on cancer therapies.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.